pocketful logo light
pocketful logo light
Transgene Biotek Ltd logo

Transgene Biotek Ltd

NSE: BSE: 526139

₹2.85

(2.89%)

Tue, 25 Aug 2026, 08:38 am

mtf coin illustrationMTF 5x

Transgene Biotek Share Price Live Chart

1 Day

(2.89%)

No Result Found

Summary

  • Market Cap (in Cr)

    23.87

  • Net Profit (in Cr)

    -0.68

  • P/B

    2.54

  • Sector P/E

    58.57

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.63

  • Interest Cover (Industry)

    1.51

  • ROCE (Industry)

    0.04

  • RONW (Industry)

    0.02

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    1.38

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    1.22

  • Interest Cover

    -1.83

Analysis

all

thumbs up icon

Pros

  • Transgene Biotek's level of debt (31.6%) compared to net worth is satisfactory (less than 40%).
  • Low level of unsold assets.
  • Transgene Biotek is good value based on assets compared to the IN Biotechs industry average.
  • 526139 outperformed the Market in India which returned -14.5% over the past year.
  • BSE:526139 is up 45.2% outperforming the Biotechs industry which returned 18.2% over the past month.
thumbs up icon

Cons

  • Unable to evaluate Transgene Biotek's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Transgene Biotek's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Transgene Biotek's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Transgene Biotek has less than a year of cash runway if free cash flow continues to grow at historical rates of 22% each year.
  • Transgene Biotek has less than a year of cash runway based on current free cash flow.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters23.6423.6423.6423.6423.64
FII00000
DII00000
Public76.3676.3676.3676.3676.36
Government00000

Read More

Technical Analysis

RSI

48.27

MACD

-0.04

50 DMA

2.99

200 DMA

2.89

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic4.783.913.463.042.592.171.30
Fibonacci3.913.583.373.042.712.502.17
Camarilla3.253.173.093.042.932.852.77

Pivots Level: Classic

R3

+1.74

4.78

R2

+0.87

3.91

R1

+0.42

3.46

3.04
3.04
Pivot Point
LTP: 2.88

S1

-0.45

2.59

S2

-0.87

2.17

S3

-1.74

1.30

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2.88

  • 20-EMA

    2.91

  • 30-EMA

    2.93

  • 50-EMA

    2.95

  • 100-EMA

    2.96

  • 200-EMA

    3.14

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 May 2026board-meetingsAccounts, Quarterly Results
13 Feb 2026board-meetingsQuarterly Results
08 Dec 2025egm
14 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
14 Nov 2025agm
12 Nov 2024agm
14 Nov 2023agm
13 Aug 2022agm
14 Aug 2021agm

Read More

Peer Comparison

Transgene Biotek Ltd logo

Transgene Biotek Ltd

Narayana Hrudayalaya Ltd logo

Narayana Hrudayalaya Ltd

Apollo Hospitals Enterprise Ltd logo

Apollo Hospitals Enterprise Ltd

Max Healthcare Institute Ltd logo

Max Healthcare Institute Ltd

Fortis Healthcare Ltd logo

Fortis Healthcare Ltd

Aster DM Healthcare Ltd logo

Aster DM Healthcare Ltd

Read More

Transgene Biotek Ltd About

Transgene Biotek is an Indian public biotech firm, established in 1990, focused on R&D for vaccines, oncology, biogenerics, and novel drug delivery (oral/nasal proteins/peptides) for unmet needs, exporting to various global markets and developing treatments for cancer, auto-immune issues, etc

Industry

Miscellaneous

Founded

1990

Headquarters

CEO

K Koteswara Rao

Employees

Contact

Website icon

Website

http://www.transgenebiotek.com

Email icon

Email

info@transgenebiotek.com

Phone icon

Phone

Location icon

Location

Plot No 69 & 70 IDA Bollaram, , Sangareddy, Telangana, 502325

Read More

Transgene Biotek Ltd Company History

YearHistory
1993
  • The company commenced commercial production.
2011
  • The company set up a wholly-owned subsidiary in Hong Kong named Transgene Biotek HK Ltd.
2012
  • Transgene readied to launch one of its block-buster drugs - TrabiDHA (DHA) formulations.
2013
  • Transgene signed a Joint Venture agreement with Atral Cipan of Portugal involving the technology transfer of Tacrolimus.
  • Transgene Biotek became the world’s first company to create and launch 50% algal DHA oil and 20% algal DHA powder.
2014
  • Sri Sarang Subhash Puranik and Shyam Shankar Das were appointed as Directors of the company.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
SAHASRAR CAPITAL PRIVATE LIMITEDbulkBuy3715707.8301 Dec 2023
GEETANJALI INVESTMENTSbulkSell8962818.1601 Dec 2023
MAYUR VIJAY PATWAbulkBuy4010008.1901 Dec 2023
GEETANJALI INVESTMENTSbulkSell7161599.124 Nov 2023
SAHASRAR CAPITAL PRIVATE LIMITEDbulkBuy3500009.1224 Nov 2023
GEETANJALI INVESTMENTSbulkSell4477288.723 Nov 2023
SH AS ENTERPRISES LLPbulkBuy4000003.3627 Mar 2014
GEETANJALI INVESTMENTSbulkBuy17854882.0219 Jun 2013
DIPESH NALINBHAI DAVEbulkBuy10000002.0319 Jun 2013
GEETANJALI INVESTMENTSbulkBuy34453501.9518 Jun 2013

Read More

Transgene Biotek Ltd News

Transgene Biotek shuts trading window

Transgene Biotek Ltd closed its trading window from July 1, 2026, until 48 hours after Q1FY27 results are declared.

20 Jun 2026

companies

Transgene Biotek reports widened net loss in FY26

Transgene Biotek reported a net loss of ₹16.53 crore for FY26, widening from ₹6.76 crore in the previous year. Revenue from operations fell to ₹2.11 crore.

29 May 2026

companies

Transgene Biotek Confirms Non-Large Corporate Status

Transgene Biotek Limited confirms to BSE that it does not meet SEBI's Large Corporate criteria as per November 2018 circular, maintaining its classification outside the large entity category.

13 Apr 2026

companies

Transgene Biotek Files Non-Applicability Notice

Transgene Biotek Limited informed BSE that SEBI Regulation 32(1) requirements for Q4FY26 are not applicable as the company had no public or rights issues during the quarter ended March 31, 2026.

13 Apr 2026

companies

Transgene Biotek Confirms Non-Applicability of SEBI Reg

Transgene Biotek Limited informs BSE that SEBI LODR Regulation 57(5) is not applicable for Q4 FY26 as the company has not issued any non-convertible securities.

13 Apr 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number